Pulmonary Nodule
Conditions
Interventions
Sugammadex Group:Administration of sugammadex sodium at a dose of 2 mg/kg at TOF = 0.4
Neostigmine Group:Administration of 50 µg/kg neostigmine and 10 µg/kg atropine at TOF = 0.4
Control Group:Administration of an equivalent volume of normal saline
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 65–80 years; 2. Scheduled for thoracoscopic lung surgery; 3. American Society of Anesthesiologists (ASA) physical status classification I–III; 4. No contraindications to surgery, such as severe cardiopulmonary insufficiency or hepatic/renal dysfunction; 5. Provision of written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. History of allergy to sugammadex or other medications used in the study; 2. Preoperative administration of neuromuscular blocking reversal agents; 3. Presence of neurological disease or severe cognitive impairment; 4. Refusal to participate in the study or inability to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuromuscular Recovery Time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Postoperative Pulmonary Complications (PPCs) within 72 Hours After Surgery;Extubation Time; Length of PACU Stay;Time to Spontaneous Breathing Recovery;Length of Hospital Stay;Inflammatory Cytokines IL-1 and IL-6;Postoperative rehabilitation quality (QoR-15); | — |
Countries
China
Contacts
Public ContactRan Jian
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed